Acute respiratory distress syndrome and severe pneumonitis after atezolizumab plus bevacizumab for hepatocellular carcinoma treatment: A case report

Figure 4 Development of acute respiratory distress syndrome three days after the combination therapy of atezolizumab and bevacizumab. The lung window of the transverse computed tomography (CT) scan obtained at the level of the left main pulmonary and main pulmonary trunk arteries shows the mixed areas of ground-glass opacity and bilateral consolidation with the anteroposterior gradient (B), compared to baseline CT which was scanned 3 and 4 d prior to atezolizumab and bevacizumab therapy and acute respiratory distress syndrome, respectively, (A) which demonstrated no inflammatory changes and minimal pulmonary fibrosis.